American Society of Hirudotherapy

Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury

Research article published in The Journal of biological chemistry (2013)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentRoversi et al. · The Journal of biological chemistry, 2013

Abstract

Molecules that simultaneously inhibit independent or co-dependent proinflammatory pathways may have advantages over conventional monotherapeutics. OmCI is a bifunctional protein derived from blood-feeding ticks that specifically prevents complement (C)-mediated C5 activation and also sequesters leukotriene B4 (LTB4) within an internal binding pocket. Here, we examined the effect of LTB4 binding on OmCI structure and function and investigated the relative importance of C-mediated C5 activation and LTB4 in a mouse model of immune complex-induced acute lung injury (IC-ALI). We describe two crystal structures of bacterially expressed OmCI: one binding a C16 fatty acid and the other binding LTB4 (C20). We show that the C5 and LTB4 binding activities of the molecule are independent of each other and that OmCI is a potent inhibitor of experimental IC-ALI, equally dependent on both C5 inhibition and LTB4 binding for full activity. The data highlight the importance of LTB4 in IC-ALI and activation of C5 by the complement pathway C5 convertase rather than by non-C proteases. The findings suggest that dual inhibition of C5 and LTB4 may be useful for treatment of human immune complex-dependent diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAcute Lung InjuryAnimalsAntigen-Antibody ComplexArthropod ProteinsCarrier ProteinsChromatography, GasComplement C5EicosanoidsFatty AcidsImmunoenzyme TechniquesLeukotriene B4Lipocalins

Summary

Peer-reviewed research on therapeutic compound development relevant to leech-derived anticoagulants and antithrombotic agents. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This study characterized OmCI, a bifunctional lipocalin protein from blood-feeding ticks that both blocks complement C5 activation and sequesters leukotriene B4 (LTB4); using two crystal structures and a mouse model of immune-complex-induced acute lung injury, the authors found OmCI is a potent inhibitor whose full effect depended equally on C5 inhibition and LTB4 binding. It is relevant to the leech-secretome drug-discovery narrative as a parallel example from another hematophagous animal: blood-feeders have evolved compact salivary molecules that simultaneously hit multiple inflammatory and coagulation pathways, the same multi-target logic that drives interest in leech salivary proteins as templates for anti-inflammatory and anticoagulant leads. Honest caveat: this is preclinical work (protein crystallography plus a single mouse disease model) on a tick-derived molecule, not a leech product and not a human study, so it speaks to mechanism and drug-design strategy rather than to any clinical benefit of hirudotherapy.

Citation

Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury.

Roversi et al. · The Journal of biological chemistry, 2013

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.